share_log

Chardan Capital Reiterates Buy on Orchestra BioMed Hldgs, Maintains $20 Price Target

Benzinga ·  May 15, 2023 04:29

Chardan Capital analyst Keay Nakae reiterates Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy and maintains $20 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment